Core Insights - Senseonics Holdings, Inc. is set to participate in the Stifel 2025 Healthcare Conference, indicating its active engagement in the healthcare investment community [1][2]. Company Overview - Senseonics is a medical technology company that specializes in developing and manufacturing long-term implantable continuous glucose monitoring (CGM) systems aimed at improving the lives of individuals with diabetes [3]. - The company's CGM systems, Eversense® 365 and Eversense® E3, feature a small sensor that is fully implanted under the skin and communicates with a smart transmitter worn externally, providing glucose data to a mobile app every 5 minutes [3]. Event Details - The Stifel 2025 Healthcare Conference will take place on November 12, 2025, at 4:40 pm ET, featuring a fireside chat format and one-on-one meetings [2]. - Interested parties can access a live and recorded webcast of the presentation through the company's website [2].

GERMANTOWN, Md., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, has announced that as a decision in the best interest of the Company and its stockholders, it will transfer the listing of its common stock from the NYSE American to the Nasdaq Global Select Market (“Nasdaq”), effective after the market closes ...

Core Insights - Senseonics Holdings, Inc. reported preliminary unaudited revenue of approximately $8.1 million for Q3 2025, marking a 91% increase compared to Q3 2024, driven by a 160% growth in new patients in the U.S. [2][10] - The company announced a reverse stock split at a ratio of 1:20, effective October 17, 2025, which will reduce the number of outstanding shares from approximately 816 million to about 41 million [3][5]. Financial Performance - The preliminary revenue of $8.1 million in Q3 2025 reflects significant growth, attributed to increased investments in direct-to-consumer marketing and the highest number of new patient starts in the company's history occurring in September 2025 [2][4]. - The company anticipates that the reverse stock split will not affect stockholders' ownership percentages significantly, aside from minor adjustments due to cash payments for fractional shares [6]. Business Strategy - Senseonics is focusing on enhancing its direct-to-consumer marketing efforts, which have led to increased awareness and adoption of its Eversense 365 continuous glucose monitoring system [4][8]. - The decision to bring the sales and marketing organization in-house is expected to bolster the company's ability to drive revenue and meet patient expectations [4]. Product Information - The Eversense CGM systems are designed for long-term glucose monitoring, with the Eversense 365 capable of continuous measurement for up to 365 days [9]. - The systems utilize a small sensor implanted under the skin, which communicates with a smart transmitter to provide real-time glucose data to users [8].

Company Overview - Senseonics Holdings, Inc. is a medical technology company focused on developing and manufacturing long-term implantable continuous glucose monitoring (CGM) systems for diabetes management [5] Upcoming Event - The company will host an in-person and virtual analyst event on June 21, 2025, at 8:00 am CT during the American Diabetes Association 85th Scientific Sessions [1] - The event will feature discussions on the next-generation Eversense® 365 CGM system, which has been approved by the FDA for individuals aged 18 and older [2] Event Details - Company management will present alongside Brian Hansen from Ascencia Diabetes Care, who will discuss the commercial launch of Eversense 365, and Gary Graf from Cotton-O'Neil Diabetes and Endocrinology Center, who will share insights on the Eversense system and its insertion procedure [3] - The event will also cover a recently announced partnership with Sequel to integrate with the twiist automated insulin delivery pump and plans to advance the pipeline of implantable CGM technology [3] - A live question and answer session will follow the formal presentations [4]

Core Viewpoint - Senseonics Holdings, Inc. has initiated an underwritten public offering of its common stock, with a potential additional 15% of shares available for underwriters to purchase [1][2]. Group 1: Offering Details - The public offering is subject to market conditions and will be made under a "shelf" registration statement filed with the SEC [3]. - TD Cowen and Barclays are the joint book-running managers for the offering, with RBC Capital Markets and Lake Street acting as bookrunners [2]. - A preliminary prospectus supplement will be filed with the SEC and will be accessible on their website [3]. Group 2: Concurrent Private Placement - Abbott Laboratories has agreed to purchase up to $25 million of Senseonics' common stock in a separate private placement, contingent on the public offering's closing [4]. - The net proceeds from both the public offering and the concurrent private placement will be used to support the launch of Eversense 365, ongoing product development, and general corporate purposes [5]. Group 3: Company Overview - Senseonics is focused on developing long-term implantable continuous glucose monitoring systems for diabetes management, with products like Eversense® 365 and Eversense® E3 [8]. - The company's CGM systems feature a small sensor that is implanted under the skin and communicates glucose data to a mobile app every 5 minutes [8].

Core Insights - Senseonics Holdings, Inc. reported a first quarter revenue of $6.3 million, representing a year-over-year growth of 24% from $5.0 million in Q1 2024 [4] - The company has partnered with Sequel to integrate its twiist™ automated insulin delivery system with the Eversense® 365 continuous glucose monitor, with a launch expected in Q3 2025 [1][9] - The company aims to improve access and flexibility for diabetes patients through its Eversense platform, with significant milestones achieved in reimbursement and product development [3] Financial Performance - Total revenue for Q1 2025 was $6.3 million, with U.S. revenue at $4.5 million and international revenue at $1.8 million, compared to $3.7 million and $1.3 million respectively in Q1 2024 [4] - Gross profit for Q1 2025 was $1.5 million, up from $0.3 million in Q1 2024, driven by increased margins on the 365-day product [5] - The net loss for Q1 2025 was $14.3 million, a reduction from a net loss of $18.9 million in Q1 2024, attributed to improved gross profit margins and reduced R&D costs [7] Expense Management - Selling, general and administrative expenses decreased by $0.4 million year-over-year to $7.7 million, primarily due to lower personnel costs and consulting fees [5] - Research and development expenses decreased by $3.1 million year-over-year to $7.3 million, mainly due to reduced spending on clinical studies following the completion of trials for the 365-day product [6] Future Outlook - The company expects full-year 2025 global net revenue to be approximately $34-38 million, anticipating a doubling of its global patient base [8] - Gross margins are projected to increase throughout 2025, with expectations of reaching between 25% and 30% for the full year [10] - Cash used in operations for 2025 is expected to be between $50 million and $60 million [10]